



Enhanced *trans* diastereoselection in the allylation of cyclic chiral *N*-acyliminium ions. Synthesis of hydroxylated indolizidines

Clécio Fernando Klitzke and Ronaldo Aloise Pilli*

Instituto de Química, UNICAMP, PO Box 6154, Campinas, SP 13083-970, Brazil

Received 11 February 2001; revised 15 June 2001; accepted 19 June 2001

Abstract—A short synthesis of hydroxylated indolizidines is reported. The key steps were the allylation of chiral cyclic *N*-acyliminium ions derived from malic and tartaric acids, followed by ring-closing metathesis. © 2001 Elsevier Science Ltd. All rights reserved.

Polyhydroxylated indolizidine alkaloids are sugar mimics which inhibit glycosidases with promising potential as drugs against viruses, cancers and diabetes.¹ A large number of representative structures were isolated from natural sources and the synthesis of the corresponding stereoisomers and analogues is actively pursued particularly for structure–activity studies.^{1,2} A variety of methods have been reported for the synthesis of indolizidine alkaloids and lentiginosine, swainsonine, and castanospermine (Fig. 1) rank among the more popular synthetic targets.

An useful synthetic approach to the structural motif found in this family of alkaloids is the allylation of the *N*-acyliminium ion derived from malic or tartaric acids. In fact, the stereochemical outcome of the addition of allyltrimethylsilane to *N*-acyliminium ions derived from imides **2** and **3** has been examined previously. Speckamp^{3a} and Scolastico^{3b} reported on the moderate *trans* preference (up to 3:1 ratio) in the addition of allyltrimethylsilane to the *O*-acetyl *N*-benzyl

acyliminium ion derived from malic acid and reversal of the sense of diastereoselection (up to 4:1 *cis:trans* ratio) was observed when *O*-TBS and *O*-benzyl derivatives were employed.^{3b,c}

In the course of an investigation aimed to prepare C-1/C8a *trans*-configured hydroxylated indolizidines, we evaluated the influence of the Lewis acid on the addition of allyltrimethylsilane and allyltributyltin to *N*-acyliminium ions⁴ derived from malic and tartaric acids.

To this purpose, *N*-allyl imide **2** was prepared from inexpensive L-malic acid in 92% yield, according to literature procedure (Scheme 1).^{3a} In order to investigate the effect of the nature of the *O*-protective group in the allylation reaction, imide **2** was converted to **3** by treatment with acetyl chloride in ethanol, followed by TBS protection. Regioselective reduction of **2** and **3**, and acetylation provided intermediates **4** and **5** in good yield.





Figure 1.

Keywords: hydroxylated indolizidines; allylation; *N*-acyliminium ions; olefin metathesis.

* Corresponding author. Fax: 55 19 37883023; e-mail: pilli@iqm.unicamp.br



Scheme 1. Reagents and conditions: (a) (i) AcCl, reflux; (ii) allylamine, CH₂Cl₂, rt; (iii) AcCl, reflux (**2**, 92%); (b) (i) AcCl, EtOH; (ii) TBSCl, imidazole, DMF (**3**, 80%); (c) (i) NaBH₄, EtOH, -23°C; (ii) Ac₂O, Et₃N, DMAP, CH₂Cl₂ (**4**, 73%; **5**, 65%); (d) see Table 1; (e) 4 mol% Grubbs' catalyst, CH₂Cl₂ (**8**, 82%; 95% d.e.); (f) (i) H₂, Pd/C, AcOEt; (ii) LiAlH₄, THF, reflux (**9**, 78%).

N-allyl lactams **4** and **5** were treated with Lewis acids (4.0 equiv.) to ensure in situ formation of the corresponding *N*-acyliminium ion, followed by the addition of the allyltrimethylsilane or tri-*n*-butylallyltin (Table 1). With most of the Lewis acid investigated, the addition to **4** proceeded in good yield but with *trans* preference within the same range as observed earlier for the *N*-benzyl analogue,^{3a,b} including the use of 1.0 equiv. of TiCl₄.⁵ However, with 4.0 equiv. of TiCl₄ preparatively useful 7:1 *trans*:*cis* ratio (83% yield) was observed (entry 6). Coordination of the oxophilic Lewis acid at the neighboring OAc group enforced by the excess of TiCl₄ may be the reason for the enhancement of *trans* selectivity.

The addition of allyltributyltin afforded low *trans* selectivity possibly as a result of its superior nucleophilicity.⁶ Surprisingly, allyltributyltin did not react when SnCl₄ or InCl₃ were used as Lewis acid (entry 9 and 10) and the use of TiCl₄ led to reversal of selectivity (entry 12). At this point, transmetalation to an allyltitanium species able to coordinate to the *O*-acetyl group cannot be ruled out to explain the *cis* preference observed in this case.⁸

In analogy with previous results,^{3c} low *cis* preference (1.8–2.2:1 ratio) was observed for 3-*O*-TBS *N*-allyl lactam **5** (entries 13–17), a result which may be rationalized through the stabilization of the emerging σ* orbital by interaction with the adjacent and antiperiplanar σ_{CH} bond.⁹

The addition of allyltrimethylsilane to *N*-allyl lactam **13** derived from (2*R*,3*R*)-tartaric acid (Scheme 2) either in the presence of 4.0 equiv. of TiCl₄ or BF₃·OEt₂ occurred without stereochemical preference (entries 18

Table 1. Effect of Lewis acid and nucleophile in the allylation of chiral cyclic *N*-acyliminium ions derived from malic and tartaric acids (See Scheme 1)^a

Entry	Substrate	Nucleophile	Lewis acid	<i>cis</i> : <i>trans</i> ratio ^b
1	4	Allylsilane	TMSOTf	1:3.5
2	4	Allylsilane	BF ₃ ·OEt ₂	1:2.5
3	4	Allylsilane	SnCl ₄	1:3.2
4	4	Allylsilane	InCl ₃	1:4
5	4	Allylsilane	TiF ₄ ^c	1:2
6	4	Allylsilane	TiCl ₄	1:7
7	4	Allylsilane	K-10 ^d	1:2.5
8	4	Allylstannane	BF ₃ ·OEt ₂	1:1.8
9	4	Allylstannane	SnCl ₄	– ^e
10	4	Allylstannane	InCl ₃	– ^e
11	4	Allylstannane	TiF ₄	1:1
12	4	Allylstannane	TiCl ₄	2:1
13	5	Allylsilane	BF ₃ ·OEt ₂	1.8:1
14	5	Allylsilane	TiCl ₄	2.2:1
15	5	Allylstannane	BF ₃ ·OEt ₂	2.2:1
16	5	Allylstannane	MgBr ₂ ^f	2.2:1
17	5	Allylstannane	TiCl ₄	1.8:1
18	13	Allylsilane	BF ₃ ·OEt ₂	1:1
19	13	Allylsilane	TiCl ₄	1:1
20	14	Allylsilane	BF ₃ ·OEt ₂	2.5:1
21	14	Allylstannane	BF ₃ ·OEt ₂	4:1

^a Unless otherwise stated, all reactions were performed in dry CH₂Cl₂ at 0°C, adding 4 equiv. of Lewis acid to a solution of the substrate and 3 equiv. of the nucleophile.

^b Determined by ¹H NMR and/or GC analysis.


^c Reaction performed in CH₃CN/CH₂Cl₂.

^d 80 mg Montmorillonite K-10 per mmol of substrate, rt.

^e 5-Hydroxy lactam recovered.

^f Reaction performed in toluene, rt.

and 19). In order to enforce *cis* addition to *N*-allyl 3-*O*-TBS lactam **14**, the use of BF₃·OEt₂ and allyltributyltin was necessary (entry 21).¹⁰



Scheme 2. Reagents and conditions: (a) (i) AcCl, reflux; (ii) allylamine, CH₂Cl₂, rt; (iii) AcCl, reflux (**11**, 99%); (b) (i) AcCl, EtOH; (ii) TBSCl, imidazole, DMF (**12**, 83%); (c) (i) NaBH₄, EtOH, -23°C; (ii) Ac₂O, Et₃N, DMAP, CH₂Cl₂ (**13**, 76%; **14**, 69%); (d) see Table 1 (**15**, 89%; *cis:trans* 1:1; **16**, 95%; *cis:trans* 2.5:1); (e) 4 mol% Grubbs' catalyst, CH₂Cl₂ (**17**, 44%; **18**, 44%); (f) (i) H₂, PtO₂, AcOEt; (ii) LiAlH₄, THF, reflux (**19**, 82%; **20**, 60%).

The results discussed above paved the way to convert **6** to bicyclic lactam **8** (82% yield) through ring-closing metathesis¹¹ which also provided a convenient way to separate the minor epimer formed by column chromatography (Scheme 1). Finally, hydrogenation and reduction of **8** afforded (1*S*,8*aR*) 1-hydroxyindolizidine(**9**), the enantiomer of the biosynthetic precursor of swainsonine.¹²

Analogously, ring-closing metathesis of a 1:1 mixture of **15** led to a separable mixture of bicyclic lactams **17** and **18**, in 88% yield (Scheme 2). After separation by column chromatography, double bond hydrogenation of **17** and **18**, followed by LiAlH₄ reduction, afforded lentiginosine¹³ (**19**) and 8*a*-*epi*-lentiginosine¹⁴ (**20**), respectively.

In conclusion, the strategy reported above provides a short synthesis of hydroxylated indolizidine alkaloids. (1*S*,8*aR*) 1-hydroxyindolizidine (**9**) was efficiently prepared in six steps and 38% overall yield from imide **2**. Lentiginosine (**19**) and 8*a*-*epi*-lentiginosine (**20**) were synthesized in six steps from imide **11** in 24 and 18% overall yield, respectively.¹⁵

Further transformations of the bicyclic lactams described herein are in progress.

Acknowledgements

The authors thank FINEP for financial support and CNPq for fellowships.

References

- Asano, N.; Nash, R. J.; Molyneux, R. J.; Fleet, G. W. J. *Tetrahedron: Asymmetry* **2000**, *11*, 1645–1680.
- (a) Burgess, K.; Henderson, I. *Tetrahedron* **1992**, *48*, 4045–4066; (b) Nemr, A. E. *Tetrahedron* **2000**, *56*, 8579–8629.
- (a) Koot, W. J.; Ginkel, R.; Kranenburg, M.; Hiemstra, H.; Louwrier, S.; Moolenaar, M. J.; Speckamp, W. N. *Tetrahedron Lett.* **1991**, *32*, 401; (b) Bernardi, A.; Micheli, F.; Potenza, D.; Scolastico, C.; Villar, R. *Tetrahedron Lett.* **1990**, *31*, 4949; (c) Thaning, M.; Wistrand, L. G. *J. Org. Chem.* **1990**, *55*, 1406.
- For recent reviews on the stereochemistry of the intermolecular Mannich reaction and applications in the synthesis of alkaloids, see: (a) Pilli, R. A.; Russowsky, D. *Trends in Org. Chem.* **1997**, *6*, 101–123; (b) Speckamp, W. N.; Moolenaar, M. J. *Tetrahedron* **2000**, *56*, 3817–3856.
- Reactions performed at -23°C and -78°C displayed the same selectivities.
- Burfeindt, J.; Patz, M.; Müller, M.; Mayr, H. *J. Am. Chem. Soc.* **1998**, *120*, 3629–3634.

7. For the use of InCl_3 as Lewis acid in *N*-acyliminium chemistry, see: Russowsky, D.; Petersen, R. Z.; Godoi, M. N.; Pilli, R. A. *Tetrahedron Lett.* **2000**, *41*, 9939–9942.
8. (a) Keck, G. E.; Abbott, D. E. *Tetrahedron Lett.* **1984**, *25*, 1883–1886; (b) Keck, G. E.; Abbott, D. E.; Boden, E. P.; Enholm, E. J. *Tetrahedron Lett.* **1984**, *25*, 3927–3930; (c) Marshall, J. A.; Hinkle, K. W. *J. Org. Chem.* **1995**, *60*, 1920–1921.
9. Cieplak, A. S. *Chem. Rev.* **1999**, *99*, 1265–1336.
10. For better results in the *syn* addition of TBS protected tartaric imide, see: Ryu, Y.; Kim, G. *J. Org. Chem.* **1995**, *60*, 103–108.
11. For some examples of ring-closing metathesis applied to the synthesis of nitrogen heterocycles, see: (a) Martin, S. F.; Chen, H. J.; Courtney, A. K.; Liao, Y.; Pätzelt, M.; Ramser, M. N.; Wagman, A. S. *Tetrahedron* **1996**, *52*, 7251–7264; (b) Tarling, C. A.; Holmes, A. B.; Markwell, R. E.; Pearson, N. D. *J. Chem. Soc., Perkin Trans. 1* **1999**, 1695–1701; (c) Maldaner, A. O.; Pilli, R. A. *Tetrahedron Lett.* **2000**, *41*, 7843–7846.
12. For the synthesis of 1-hydroxyindolizidine, see: (a) Harris, C. M.; Harris, T. M. *Tetrahedron Lett.* **1987**, *28*, 2559–2562; (b) Harris, C. M.; Schneider, M. J.; Ungemach, F. S.; Hill, J. E.; Harris, T. M. *J. Am. Chem. Soc.* **1988**, *110*, 940–949; (c) Takahata, H.; Banba, Y.; Momose, T. *Tetrahedron: Asymmetry* **1990**, *1*, 763–764.
13. For other synthetic approaches to lentiginosine, see: (a) Yoda, H.; Kitayama, H.; Katagiri, T.; Takabe, K. *Tetrahedron: Asymmetry* **1993**, *4*, 1455–1456; (b) Nukui, S.; Sodeoka, M.; Sasai, H.; Shibasaki, M. *J. Org. Chem.* **1995**, *60*, 398–404; (c) Brandi, A.; Cicchi, S.; Cordero, F. M.; Frignoli, R.; Goti, A.; Picasso, S.; Vogel, P. *J. Org. Chem.* **1995**, *60*, 6806–6812; (d) Ha, D. C.; Yun, C. S.; Lee, Y. *J. Org. Chem.* **2000**, *65*, 621–623; (e) Yoda, H.; Katoh, H.; Ujihara, Y.; Takabe, K. *Tetrahedron Lett.* **2001**, *42*, 2509–2512.
14. For the synthesis of 8a-*epi*-lentiginosine, see: Paolucci, C.; Musiani, L.; Venturelli, F.; Fava, A. *Synthesis* **1997**, 1415–1418.
15. All new compounds gave spectral and analytical data in accordance with the proposed structures. Compound **8**: $[\alpha]_{\text{D}}^{26} +14.3$ (*c* 2.37, CHCl_3); IR (neat) 3037, 2929, 2848, 1737, 1699, 1656, 1440, 1375, 1236, 1055; ^1H NMR (300 MHz, CDCl_3): δ 1.95–2.09 (m, 1H), 2.05 (s, 3H), 2.37–2.47 (m, 2H), 2.77 (dd, *J* 8.1 and 18.4 Hz, 1H), 3.50–3.57 (m, 2H), 4.32 (dd, *J* 2.7 and 18.4 Hz, 1H), 4.94 (dt, *J* 2.5 and 7.7 Hz, 1H), 5.64–5.68 (m, 1H), 5.73–5.78 (m, 1H); ^{13}C NMR (75 MHz, CDCl_3): δ 20.72, 28.62, 36.30, 39.85, 59.28, 71.67, 123.77, 123.81, 170.63, 170.66; HRMS (EI) calcd for $\text{C}_{10}\text{H}_{13}\text{NO}_3$ (M^+) 195.0895, found 195.0895. Compound **17**: $[\alpha]_{\text{D}}^{24} +94.5$ (*c* 1.35, CHCl_3); IR (neat) 3016, 2936, 2852, 1749, 1725, 1653, 1432, 1371, 1239, 1058; ^1H NMR (300 MHz, CDCl_3): δ 2.13 (s, 3H), 2.16 (s, 3H), 2.19–2.26 (m, 1H), 2.57 (dl, *J* 16.8 Hz, 1H), 3.51 (dt, *J* 4.6 and 10.5 Hz, 1H), 3.64 (d, *J* 18.8 Hz, 1H), 4.33 (dd, *J* 2.9 and 18.8 Hz, 1H), 5.08 (dd, *J* 5.1 and 5.3 Hz, 1H), 5.46 (dd, *J* 1.4 and 5.3 Hz, 1H), 5.72–5.75 (m, 1H), 5.82–5.85 (m, 1H); ^{13}C NMR (75 MHz, CDCl_3): δ 20.67, 20.75, 30.02, 40.16, 55.22, 74.39, 77.69, 122.29, 123.53, 166.44, 170.00, 170.36; HRMS (EI) calcd for $\text{C}_{12}\text{H}_{15}\text{NO}_5$ (M^+) 253.0950, found 253.0950. Compound **18**: $[\alpha]_{\text{D}}^{24} +167.1$ (*c* 1.12, CHCl_3); IR (neat) 3040, 2935, 2858, 1744, 1715, 1595, 1433, 1375, 1256, 1069; ^1H NMR (300 MHz, CDCl_3): δ 2.01–2.19 (m, 2H), 2.14 (s, 3H), 2.17 (s, 3H), 3.61 (d, *J* 18.3 Hz, 1H), 4.02 (ddd, *J* 4.4, 6.9 and 11.2 Hz, 1H), 4.38 (dd, *J* 2.9 and 18.3 Hz, 1H), 5.43–5.50 (m, 2H), 5.70–5.74 (m, 1H), 5.80–5.87 (m, 1H); ^{13}C NMR (75 MHz, CDCl_3): δ 20.37, 20.51, 24.95, 40.46, 52.35, 72.71, 73.71, 123.59, 123.84, 165.98, 170.09, 170.44; HRMS (EI) calcd for $\text{C}_{12}\text{H}_{15}\text{NO}_5$ (M^+) 253.0950, found 253.0956. Spectral and analytical data of **9**, **19**, and **20** are in agreement with those described in Refs. 12, 13 and 14, respectively.